REVEAL PEDIATRIC STUDY: AN OPEN-LABEL, RANDOMIZED, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF THE SAFETY TOLERABILITY AND EFFICACY OF A SINGLE IT ADMINISTRATION OF TSHA-102, AN AAV9-DELIVERED GT, FOR THE TREATMENT OF PEDIATRIC FEMALES WITH RTT

Registry ID

TSHA-102-CL-102

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

TAYSHA GENE THERAPIES INC.

Start date

2024-10-21

Last update

2024-06-21

Conditions

• RETT SYNDROME

Related clinical trials

• AN OPEN-LABEL, RANDOMIZED, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF THE SAFETY AND PRELIMINARY EFFICACY OF A SINGLE INTRATHECAL ADMINISTRATION OF TSHA-102, AN AAV9-DELIVERED GENE THERAPY, IN THE TREATMENT OF ADULT FEMALES WITH RETT SYNDROME

View on source registry